Navigation Links
Parkinson's Disease Medication Triggers Destructive Behaviors

Mayo Clinic Study Identifies At-Risk Patients


*Parkinson's drug may cause destructive behaviors

*The patients affected are taking a therapeutic dose of the drug

*Decreasing the dosage may eliminate the problem

ROCHESTER, Minn., April 8 /PRNewswire-USNewswire/ -- A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.

VIDEO ALERT: Additional audio and video resources including excerpts from an interview with Dr. J. Michael Bostwick describing the research, are available on the Mayo Clinic News Blog.

The study extends findings from two Mayo case series published in 2005 that reported a connection between dopamine agonist medications and compulsive gambling or hypersexuality.

Dopamine agonists are a class of drugs that include pramipexole and ropinirole. They are commonly used to treat Parkinson's disease, but low doses also are used for restless legs syndrome. They uniquely stimulate brain limbic circuits, which are thought to be fundamental substrates for emotional, reward and hedonistic behaviors.

"The 2005 case series alerted us that something bad was happening to some unfortunate people. This study was done to assess the likelihood that this effect would happen to the average Parkinson's patient treated with these agents," says J. Michael Bostwick, M.D., Mayo Clinic psychiatrist who spearheaded the new study. It is published in the April issue of Mayo Clinic Proceedings.

The researchers analyzed the medical records of patients with Parkinson's disease residing in counties surrounding Rochester, Minn., who received their primary neurological care at Mayo Clinic in Rochester between 2004 and 2006. This group included 267 patients. Of those, 66 were taking dopamine agonists for their Parkinson's disease. Of those 66, 38 were taking the drugs in therapeutic doses (doses expected to be at least minimally beneficial).

The findings were definitive. Seven patients experiencing new-onset compulsive gambling or hypersexuality were taking dopamine agonists in therapeutic doses. None of the other Parkinson's disease patients developed compulsive gambling habits or hypersexuality, including the 28 patients on subtherapeutic dopamine agonist doses or the other 201 patients not taking dopamine agonists. None of the 178 patients treated only with the standard drug for Parkinson's disease, carbidopa/levodopa, developed these behaviors.

"It is crucial for clinicians prescribing dopamine agonists to apprise patients as well as their spouses or partners about this potential side effect. The onset can be insidious and overlooked until life-altering problems develop," says J. Eric Ahlskog, M.D., Ph.D., Mayo Clinic neurologist who co-authored and treated many of the patients in the 2005 study. "It also is worth noting that the affected patients were all taking therapeutic doses. Very low doses, such as those used to treat restless legs syndrome, carry much less risk."

"For some patients, a reduction in the dose of the dopamine agonist may prove to be sufficient treatment," says Dr. Ahlskog, "although total elimination of the offending drug is often necessary."

A peer-review journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online at

About Mayo Clinic

Mayo Clinic is the first and largest integrated, not-for-profit group practice in the world. Doctors from every medical specialty work together to care for patients, joined by common systems and a philosophy that "the needs of the patient come first." More than 3,300 physicians, scientists and researchers and 46,000 allied health staff work at Mayo Clinic, which has sites in Rochester, Minn., Jacksonville, Fla., and Scottsdale/Phoenix, Ariz. Collectively, the three locations treat more than half a million people each year. To obtain the latest news releases from Mayo Clinic, go to ( is available as a resource for your health stories. For more on Mayo Clinic research, go to

SOURCE Mayo Clinic
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
2. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
3. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
4. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
5. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
7. Metastatic Bone Disease Patients Can Walk in Lazarus Footsteps
8. Tevas Azilect Use Dramatically Increases in Second-Line Therapy for the Treatment of Parkinsons Disease
9. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
10. The Childrens Hospital of Philadelphia: New Gene-Searching Method Uncovers Possible New Targets for Crohns Disease Drugs
11. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... announced that Chief Executive Officer Antonius Schuh, Ph.D., is ... th Annual Piper Jaffray Healthcare Conference. ... New York Palace Hotel in New York ... p.m. EST. Mr. Schuh will be available for one-on-one ...
(Date:11/25/2015)... Nov. 25, 2015 Endo International plc (NASDAQ: ... Silva , President and CEO, will discuss corporate updates at ... New York on Wednesday, December 2, ... Click on Investor Relations, and then the link to the ... presentation,s start time to visit the site and download any ...
(Date:11/25/2015)... November 25, 2015 Asia ... to which BioLight and the New Investors will make ... ("IOPtima") via a private placement. The financing will help ... IOPtimate™ system used in the treatment of glaucoma, as ... for the IOPtimate™ system with the U.S. Food and ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, ... from Bronx, N.Y. “I thought there had to be a convenient and comfortable way ... , The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for ... The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout 2016 ...
(Date:11/25/2015)... ... 25, 2015 , ... An unlikely combination of recycled plastic ... for homeless people to have a more dignified and comfortable night’s sleep. , ... are repurposing plastic bags into sleeping mats for the homeless. The project, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has focused on providing comprehensive solutions involving adult stem cell therapies to patients ... officially deemed the “Regenestem” name as a Registered Trademark (RTM). , Organizations are ...
Breaking Medicine News(10 mins):